Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed to the Blackstone-backed startup six years ago.

With this acquisition, LipoVation becomes a wholly owned subsidiary of Revium Rx, aligning with the company’s renewed commitment to drug delivery innovation. Revium Rx is developing a portfolio of ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Braftovi is a targeted medicine aimed at a particular mutation, V600E, to the BRAF gene. BRAF mutations occur in about 10% of people with colorectal cancer, and the V600E is the most common among them ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...